Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Expert Guidance on Optimizing Treatment Strategies for Acute Lymphoblastic Leukemia
  • CME
  • CE

Amir Fathi, MD
Released: April 16, 2020

Measurable Residual Disease in ALL

MRD and Its Status as Prognostic Factor for OS in ALL

An important feature of studies and treatment paradigms for B‑cell ALL is the impact of MRD. MRD is the low level presence of lymphoblasts following initial therapy that are not detected using traditional methods such as microscopy.[18] MRD can be detected by a variety of sensitive methods, including flow cytometry for leukemia‑associated immunophenotypes, as well as by FISH or PCR testing for leukemia‑specific fusion transcripts or gene rearrangements.[19]

Low‑level molecular disease in patients with ALL can be detected following induction or consolidation before transplant, and has been associated with worse survival and poor prognosis, compared with those without evidence of MRD.[20]

MRD Overview

Patients with newly diagnosed B‑cell ALL receive intensive treatments with the aim of suppressing their lymphoid blast population to a certain level. If that level is below molecular detection, as measured by sensitive MRD techniques, then the likelihood that their disease will reemerge in the future is significantly lower.[21] If the suppression of lymphoid blasts is not sufficient and lymphoid blasts are still detected by MRD testing, then their disease is more likely to relapse subsequently.

Methods for MRD Quantification in ALL

A variety of methods for MRD quantification are available, including flow cytometry, PCR testing, and next-generation sequencing that can increase the sensitivity offered in certain settings. Regardless of which method is used, MRD status is increasingly important to establish risk of relapse in patients receiving standard therapies for B‑cell ALL.

MRD Status Before and After HCT Predicts RFS and OS

A common approach to the treatment of B‑cell ALL, particularly for those with high-risk disease, is to suppress the lymphoid blast population, achieve a state of deep molecular remission with induction and/or consolidation therapy, and thereafter, increase the chance of cure with a consolidative SCT. A study in which 43 patients with high-risk ALL who received SCT found that individuals with evidence of MRD had worse survival outcomes vs those with no evidence of MRD.[22]

Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by educational grants from
Amgen
Jazz Pharmaceuticals, Inc.
Pfizer Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue